Identification

Name
Rucaparib
Accession Number
DB12332
Type
Small Molecule
Groups
Approved, Investigational
Description

Rucaparib is a potent mammalian poly(ADP-ribose) polymerase (PARP) 1, 2 and 3 inhibitor with anticancer properties. PPAR is an enzyme that plays an essential role in DNA repair by activating response pathways and facilitating repair [2], and defects in these repair mechanisms have been demonstrated in various malignancies, including cancer. Regulation of repair pathways is critical in promoting necessary cell death. BRCA genes are tumor suppressor genes mediate several cellular process including DNA replication, transcription regulation, cell cycle checkpoints, apoptosis, chromatin structuring and homologous recombination (HR). Homologous recombination deficiency (HRD), along with PPAR inhibition, is a vulnerability that enhances the cell death pathway when the single mutations alone would permit viability. Ovarian cancer commonly possesses defects in DNA repair pathways such as HRD due to BRCA mutations or otherwise.

There are three main types of ovarian cancer: epithelial (90%), germ cell (5%) and sex cord stromal cell (5%). Epithelial ovarian, being the most common, fifth leading cause of cancer-related deaths in women in the United States. Advanced ovarian cancer particularly poses challenges due to reduced therapeutic response rates from standard platinum-based chemotherapy and overall survival rates. Rucaparib has shown to induce cytotoxicity in tumor cell lines with deficiencies in BRCA1/2 and other DNA repair genes [FDA Label]. Of all the BRCA1/2 mutations in ovarian cancer, most are due to germline mutations (18%), and approximately 7% represent somatic mutations acquired within the tumor [4].

The indication of rucaparib as an oral monotherapy in patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer was granted accelerated approval in 2016 for selected patients who have previously received greater than two lines of platinum-based therapy. It is currently marketed in the US under the brand name Rubraca that contains rucaparib camsylate as the active ingredient. The identification of patients who are eligible for rucaparib therapy is performed via in vitro diagnostic tests to detect the presence of a deleterious BRCA mutation (germline and/or somatic). The FDA-approved test qualitatively detects sequence alterations in BRCA1 and BRCA2 (BRCA1/2) genes. More information can be found on the FDA Website [9].

While rucaparib is indicated for deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, there is evidence that its antitumor activity is also clinically effective against ovarian tumors with high homologous recombination deficiency (HRD) loss of heterozygosity (LOH) [4].

Structure
Thumb
Synonyms
Not Available
External IDs
AG-14447
Product Ingredients
IngredientUNIICASInChI Key
Rucaparib camsylate41AX9SJ8KO1859053-21-6INBJJAFXHQQSRW-STOWLHSFSA-N
Rucaparib phosphateH3M9955244459868-92-9FCCGJTKEKXUBFZ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RubracaTablet, film coated200 mg/1OralClovis Oncology, Inc.2016-12-19Not applicableUs
RubracaTablet, film coated250 mg/1OralClovis Oncology, Inc.2017-05-01Not applicableUs
RubracaTablet, film coated300 mg/1OralClovis Oncology, Inc.2016-12-19Not applicableUs
Categories
UNII
8237F3U7EH
CAS number
283173-50-2
Weight
Average: 323.371
Monoisotopic: 323.143390375
Chemical Formula
C19H18FN3O
InChI Key
HMABYWSNWIZPAG-UHFFFAOYSA-N
InChI
InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)
IUPAC Name
6-fluoro-2-{4-[(methylamino)methyl]phenyl}-3,10-diazatricyclo[6.4.1.0^{4,13}]trideca-1,4,6,8(13)-tetraen-9-one
SMILES
CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3

Pharmacology

Indication

Indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for rucaparib.

Structured Indications
Pharmacodynamics

Rucaparib has been shown to decrease tumor growth in mouse xenograft models of human cancer with or without deficiencies in BRCA [FDA Label].

The effect of multiple doses of rucaparib on QTc interval was evaluated in an open-label single-arm study in 56 patients with solid tumors who were administered continuous doses of rucaparib ranging from 40 mg once daily (0.03 times the approved recommended dosage) to 840 mg twice daily (1.4 times the approved recommended dosage). The mean QTcF increase from baseline (90% confidence interval [CI]) in population pharmacokinetics estimated 95% percentile Cmax (3019 ng/mL) at steady state of 600 mg rucaparib twice daily was 14.9 msec (11.1-18.7 msec) [FDA Label].

Mechanism of action

Poly (ADP-ribose) polymerase (PARP) enzymes play a role in DNA repair. PPAR-1 is responsible in repairing single stranded breaks (SSBs) in base excision repair (BER). PARP1 also functions in nonhomologous end-joining (NHEJ) regulation, chromatin remodeling and homologous recombination (HR) DNA repair pathways [2]. When PARP is inhibited, single-strand breaks become double-strand breaks, which are typically repaired via homologous recombination [2]. Pre-existing homologous recombination deficiency (HRD) may occur through mutations in the BRCA1 or BRCA2 genes, which confers persistant cell repair and growth in cancer cells.

Rucaparib is an inhibitor of PARP-1, PARP-2, and PARP-3. Via an inhibitory effect on the PARP enzymatic activity, rucaparib decreases the formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death [FDA Label]. It is proposed that PARP inhibition specifically targets tumor cells with preexisting HRD, such as those cells possessing mutations in the BRCA1 or BRCA2 genes [4]. Rucaparib induces synthetic lethality by disrupting ingle- and double-strand repair pathways leading to tumor cell death. It is also suggested that PARP inhibition can lead to trapping of PARP-1 enzyme on damaged DNA, effectively preventing continuation of the DNA repair process; defective BRCA1 recruitment to damaged DNA; and activation of alternative DNA repair such as error-prone nonhomologous end joining (NHEJ) or alternative end joining pathways leading to mutations or chromosomal changes and ultimately cell death [4].

TargetActionsOrganism
APoly [ADP-ribose] polymerase 1
antagonist
Human
APoly [ADP-ribose] polymerase 2
antagonist
Human
APoly [ADP-ribose] polymerase 3
antagonist
Human
Absorption

Rucaparib demonstrates a linear pharmacokinetic properties over a dose range from 240 to 840 mg twice daily with time-independence and dose-proportionality. The mean steady-state rucaparib Cmax was 1940 ng/mL (54% coefficient of variation [CV]) and AUC0-12h was 16900 h⋅ng/mL (54% CV) at the approved recommended dosage. The time to reach the steady-state peak plasma concentration (Tmax) was 1.9 hours at the recommended dosage. The mean absolute bioavailability of rucaparib immediate-release tablet was 36% with a range from 30% to 45%. Following a high-fat meal, the Cmax was increased by 20% and AUC 0-24h was increased by 38%, and T max was delayed by 2.5 hours, as compared to dosing under fasted conditions [FDA Label].

Volume of distribution

Following a single intravenous dose of 12mg to 40mg rucaparib, the steady-state volume of distribution was 113L to 262L [FDA Label].

Protein binding

In vitro, the protein binding of rucaparib was 70% in human plasma at therapeutic concentrations. Rucaparib preferentially distributed to red blood cells with a blood-to-plasma concentration ratio of 1.83 [FDA Label].

Metabolism

According to in vitro studies, rucaparib is primarily metabolized by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4 [FDA Label].

Route of elimination

Fecal excretion was the major route of elimination, accounting for ≥ 79% of the total dose.

Half life

Following a single oral dose of 600mg rucaparib, the mean terminal half life (t1/2) was 17-19 hours [FDA Label].

Clearance

Following continuous 600mg rucaparib administration orally twice daily, the apparent clearance ranges from 15.3 to 79.2 L/hour. The clearance ranged from 13.9 to 18.4 L/hour, following a single intravenous dose of rucaparib 12 mg to 40 mg [FDA Label].

Toxicity

According to a bacterial reverse mutation (Ames) test, rucaparib has shown to be mutagenic. It was also clastogenic in an in vitro chromosomal aberration assay in cultured human lymphocytes. Rucaparib has a genotoxic potential. Based on its mechanism of action and findings from animal studies, rucaparib can cause fetal harm when administered to a pregnant woman. Female patients of reproductive potential should be advised to use effective contraception during treatment and for 6 months following the last dose of rucaparib [FDA Label].

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Rucaparib.Experimental, Illicit
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Rucaparib.Approved, Investigational
AbirateroneThe serum concentration of Rucaparib can be increased when it is combined with Abiraterone.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Rucaparib.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Rucaparib.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Rucaparib.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Rucaparib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Rucaparib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Rucaparib.Experimental
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Rucaparib.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Rucaparib.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Rucaparib.Approved
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Rucaparib.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Rucaparib.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Rucaparib.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Rucaparib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Rucaparib.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Rucaparib.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Rucaparib.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Rucaparib.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Rucaparib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Rucaparib.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Rucaparib.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Rucaparib.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Rucaparib.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Rucaparib.Approved, Withdrawn
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Rucaparib.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Rucaparib.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Rucaparib.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Rucaparib.Approved
AmiodaroneThe metabolism of Rucaparib can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Rucaparib.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Rucaparib.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Rucaparib.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Rucaparib.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Rucaparib.Approved, Vet Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Rucaparib.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Rucaparib.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Rucaparib.Approved, Investigational
AnagrelideThe metabolism of Anagrelide can be decreased when combined with Rucaparib.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Rucaparib.Approved, Investigational, Withdrawn
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Rucaparib.Approved, Investigational
ApalutamideThe serum concentration of Rucaparib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Rucaparib.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Rucaparib.Approved, Investigational
AprepitantThe serum concentration of Rucaparib can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Rucaparib.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Rucaparib.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Rucaparib.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Rucaparib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Rucaparib.Approved, Investigational
ArtemetherThe metabolism of Rucaparib can be decreased when combined with Artemether.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Rucaparib.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Rucaparib.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Rucaparib.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Rucaparib can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Rucaparib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Rucaparib is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Rucaparib.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Rucaparib.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Rucaparib.Approved
AzithromycinThe metabolism of Rucaparib can be decreased when combined with Azithromycin.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Rucaparib.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Rucaparib.Approved, Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Rucaparib.Approved
BendamustineThe metabolism of Bendamustine can be decreased when combined with Rucaparib.Approved, Investigational
BenidipineThe metabolism of Benidipine can be decreased when combined with Rucaparib.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Rucaparib.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Rucaparib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Rucaparib.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Rucaparib.Approved, Withdrawn
BetaxololThe metabolism of Rucaparib can be decreased when combined with Betaxolol.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Rucaparib.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Rucaparib.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Rucaparib.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Rucaparib.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Rucaparib.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Rucaparib.Approved
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Rucaparib.Approved, Investigational
BoceprevirThe metabolism of Rucaparib can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Rucaparib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Rucaparib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Rucaparib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Rucaparib.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Rucaparib.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Rucaparib.Approved, Investigational
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Rucaparib.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Rucaparib.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Rucaparib.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rucaparib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Rucaparib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Rucaparib.Approved
BufuralolThe metabolism of Bufuralol can be decreased when combined with Rucaparib.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Rucaparib.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Rucaparib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Rucaparib can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Rucaparib.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Rucaparib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rucaparib.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Rucaparib.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Rucaparib.Approved, Investigational
CaffeineThe metabolism of Rucaparib can be decreased when combined with Caffeine.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Rucaparib.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Rucaparib.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Rucaparib.Experimental
Candesartan cilexetilThe metabolism of Candesartan cilexetil can be decreased when combined with Rucaparib.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Rucaparib.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Rucaparib.Approved
CarbamazepineThe metabolism of Rucaparib can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Rucaparib.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Rucaparib.Approved, Investigational
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Rucaparib.Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Rucaparib.Approved, Investigational
CarteololThe metabolism of Carteolol can be decreased when combined with Rucaparib.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Rucaparib.Approved, Investigational
CelecoxibThe metabolism of Rucaparib can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Rucaparib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Rucaparib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Rucaparib.Approved, Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Rucaparib.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Rucaparib.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Rucaparib.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Rucaparib.Approved, Illicit, Investigational
ChloroquineThe metabolism of Rucaparib can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Rucaparib.Approved
ChlorpromazineThe metabolism of Rucaparib can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Rucaparib.Approved, Investigational
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Rucaparib.Approved
CholecalciferolThe metabolism of Rucaparib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Rucaparib.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Rucaparib.Approved, Investigational
CimetidineThe metabolism of Rucaparib can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Rucaparib can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Rucaparib.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Rucaparib.Approved
ClarithromycinThe metabolism of Rucaparib can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Rucaparib can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Rucaparib.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Rucaparib.Approved, Vet Approved
ClobazamThe metabolism of Rucaparib can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Rucaparib.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Rucaparib.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Rucaparib.Investigational
ClomipramineThe metabolism of Rucaparib can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Rucaparib.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Rucaparib.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Rucaparib resulting in a loss in efficacy.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Rucaparib.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Rucaparib.Approved, Illicit
ClotrimazoleThe metabolism of Rucaparib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Rucaparib can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Rucaparib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Rucaparib.Approved, Investigational
CocaineThe metabolism of Rucaparib can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Rucaparib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Rucaparib.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Rucaparib.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Rucaparib.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Rucaparib.Approved, Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Rucaparib.Approved, Investigational
CrizotinibThe metabolism of Rucaparib can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Rucaparib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Rucaparib.Approved, Investigational
CyclosporineThe metabolism of Rucaparib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Rucaparib.Experimental
Cyproterone acetateThe serum concentration of Rucaparib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Rucaparib.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rucaparib.Approved
DabrafenibThe serum concentration of Rucaparib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Rucaparib.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Rucaparib.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Rucaparib.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Rucaparib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Rucaparib.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Rucaparib.Approved, Investigational
DarifenacinThe metabolism of Rucaparib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Rucaparib can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Rucaparib.Approved
DasatinibThe serum concentration of Rucaparib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Rucaparib.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Rucaparib.Approved, Investigational
DeferasiroxThe serum concentration of Rucaparib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Rucaparib.Approved, Investigational
DelavirdineThe metabolism of Rucaparib can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Rucaparib can be decreased when combined with Desipramine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Rucaparib.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Rucaparib.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Rucaparib.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Rucaparib.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Rucaparib.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Rucaparib.Approved, Investigational
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Rucaparib.Approved, Investigational
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Rucaparib.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Rucaparib.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Rucaparib.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Rucaparib.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Rucaparib.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Rucaparib.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Rucaparib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Rucaparib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Rucaparib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rucaparib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Rucaparib.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Rucaparib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Rucaparib.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Rucaparib.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Rucaparib.Approved, Investigational
DiltiazemThe metabolism of Rucaparib can be decreased when combined with Diltiazem.Approved, Investigational
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Rucaparib.Approved
DiphenhydramineThe metabolism of Rucaparib can be decreased when combined with Diphenhydramine.Approved, Investigational
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Rucaparib.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Rucaparib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rucaparib.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Rucaparib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Rucaparib.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Rucaparib.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Rucaparib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Rucaparib.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Rucaparib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Rucaparib.Approved
DosulepinThe metabolism of Rucaparib can be decreased when combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Rucaparib.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Rucaparib.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Rucaparib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Rucaparib.Approved, Investigational
DoxycyclineThe metabolism of Rucaparib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Rucaparib.Approved, Illicit
DronedaroneThe metabolism of Rucaparib can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Rucaparib can be decreased when combined with Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Rucaparib.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Rucaparib.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Rucaparib.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Rucaparib.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Rucaparib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Rucaparib.Approved
EltrombopagThe serum concentration of Rucaparib can be increased when it is combined with Eltrombopag.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Rucaparib.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Rucaparib.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Rucaparib.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Rucaparib.Investigational
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Rucaparib.Approved, Investigational
EnzalutamideThe serum concentration of Rucaparib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Rucaparib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Rucaparib.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Rucaparib.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Rucaparib.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Rucaparib.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rucaparib.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Rucaparib.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Rucaparib.Approved, Investigational
ErythromycinThe metabolism of Rucaparib can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Rucaparib.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Rucaparib.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Rucaparib.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Rucaparib.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Rucaparib.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Rucaparib.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Rucaparib.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Rucaparib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Rucaparib.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Rucaparib.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Rucaparib.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Rucaparib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Rucaparib.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Rucaparib.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Rucaparib.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Rucaparib.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Rucaparib.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Rucaparib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Rucaparib.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Rucaparib.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Rucaparib.Approved, Investigational
FamotidineThe metabolism of Famotidine can be decreased when combined with Rucaparib.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Rucaparib.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Rucaparib.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Rucaparib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Rucaparib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Rucaparib.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Rucaparib.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Rucaparib.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Rucaparib.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Rucaparib is combined with Flibanserin.Approved, Investigational
FluconazoleThe metabolism of Rucaparib can be decreased when combined with Fluconazole.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Rucaparib.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Rucaparib.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Rucaparib.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Rucaparib.Approved, Investigational
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Rucaparib.Approved
FluoxetineThe metabolism of Rucaparib can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Rucaparib.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Rucaparib.Approved, Illicit, Investigational
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Rucaparib.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Rucaparib.Approved, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Rucaparib.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Rucaparib.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Rucaparib.Approved
FluvoxamineThe metabolism of Rucaparib can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Rucaparib.Approved, Investigational
FosamprenavirThe metabolism of Rucaparib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Rucaparib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Rucaparib can be increased when combined with Fosphenytoin.Approved, Investigational
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Rucaparib.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Rucaparib.Approved, Investigational
Fusidic AcidThe serum concentration of Rucaparib can be increased when it is combined with Fusidic Acid.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Rucaparib.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Rucaparib.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Rucaparib.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Rucaparib.Approved
GenisteinThe metabolism of Genistein can be decreased when combined with Rucaparib.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Rucaparib.Experimental
GliclazideThe metabolism of Gliclazide can be decreased when combined with Rucaparib.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Rucaparib.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Rucaparib.Approved, Investigational
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Rucaparib.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Rucaparib.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Rucaparib.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Rucaparib.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Rucaparib.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Rucaparib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Rucaparib.Approved
HaloperidolThe metabolism of Rucaparib can be decreased when combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Rucaparib.Approved, Vet Approved
HesperetinThe metabolism of Hesperetin can be decreased when combined with Rucaparib.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Rucaparib.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Rucaparib.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Rucaparib.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Rucaparib.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Rucaparib.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Rucaparib.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Rucaparib.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Rucaparib.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Rucaparib.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Rucaparib.Approved
IdelalisibThe metabolism of Rucaparib can be decreased when combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Rucaparib resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Rucaparib.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Rucaparib.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Rucaparib.Approved, Investigational
ImipramineThe metabolism of Rucaparib can be decreased when combined with Imipramine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Rucaparib.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Rucaparib.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Rucaparib.Approved
IndinavirThe metabolism of Rucaparib can be decreased when combined with Indinavir.Approved
IndisulamThe metabolism of Indisulam can be decreased when combined with Rucaparib.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Rucaparib.Approved, Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Rucaparib.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Rucaparib.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Rucaparib.Approved, Investigational
IsavuconazoleThe serum concentration of Rucaparib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Rucaparib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Rucaparib can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Rucaparib.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Rucaparib.Approved
IsradipineThe metabolism of Rucaparib can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Rucaparib can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Rucaparib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Rucaparib.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Rucaparib.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Rucaparib.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Rucaparib.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Rucaparib.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Rucaparib.Approved, Investigational
KetoconazoleThe metabolism of Rucaparib can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Rucaparib.Approved, Vet Approved
LabetalolThe metabolism of Labetalol can be decreased when combined with Rucaparib.Approved
LacidipineThe metabolism of Lacidipine can be decreased when combined with Rucaparib.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Rucaparib.Experimental
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Rucaparib.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Rucaparib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Rucaparib.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Rucaparib.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Rucaparib.Approved, Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Rucaparib.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Rucaparib.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Rucaparib.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Rucaparib.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Rucaparib.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Rucaparib.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Rucaparib.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Rucaparib.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Rucaparib.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Rucaparib.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Rucaparib.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Rucaparib.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Rucaparib.Investigational
LidocaineThe metabolism of Rucaparib can be decreased when combined with Lidocaine.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Rucaparib.Approved, Investigational
LobeglitazoneThe metabolism of Rucaparib can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Rucaparib.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Rucaparib.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Rucaparib.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Rucaparib.Approved
LopinavirThe metabolism of Rucaparib can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Rucaparib.Approved, Investigational
LorcaserinThe metabolism of Rucaparib can be decreased when combined with Lorcaserin.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Rucaparib.Approved, Investigational
LorpiprazoleThe serum concentration of Rucaparib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Rucaparib.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Rucaparib.Approved, Investigational
LuliconazoleThe serum concentration of Rucaparib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Rucaparib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Rucaparib can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Rucaparib.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Rucaparib.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Rucaparib.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Rucaparib.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Rucaparib.Approved
MalathionThe metabolism of Malathion can be decreased when combined with Rucaparib.Approved, Investigational
ManidipineThe metabolism of Rucaparib can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Rucaparib.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Rucaparib.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Rucaparib.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Rucaparib.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Rucaparib.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Rucaparib.Approved, Investigational
MelatoninThe metabolism of Melatonin can be decreased when combined with Rucaparib.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Rucaparib.Approved, Vet Approved
MenadioneThe metabolism of Menadione can be decreased when combined with Rucaparib.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Rucaparib.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Rucaparib.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Rucaparib.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Rucaparib.Approved, Investigational
MestranolThe metabolism of Mestranol can be decreased when combined with Rucaparib.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Rucaparib.Experimental
MethadoneThe metabolism of Rucaparib can be decreased when combined with Methadone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Rucaparib.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Rucaparib.Illicit, Withdrawn
MethotrimeprazineThe metabolism of Rucaparib can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Rucaparib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Rucaparib.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Rucaparib.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Rucaparib.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Rucaparib.Approved
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Rucaparib.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Rucaparib.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Rucaparib.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Rucaparib.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Rucaparib.Experimental
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Rucaparib.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Rucaparib.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Rucaparib.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Rucaparib.Experimental
MexiletineThe metabolism of Rucaparib can be decreased when combined with Mexiletine.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Rucaparib.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Rucaparib.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Rucaparib.Approved, Illicit
MidostaurinThe metabolism of Rucaparib can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Rucaparib can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Rucaparib.Approved
MirabegronThe metabolism of Rucaparib can be decreased when combined with Mirabegron.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Rucaparib.Approved
MitotaneThe serum concentration of Rucaparib can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Rucaparib.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Rucaparib.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Rucaparib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Rucaparib.Approved, Investigational
MuraglitazarThe metabolism of Muraglitazar can be decreased when combined with Rucaparib.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Rucaparib.Approved, Investigational
NabumetoneThe metabolism of Nabumetone can be decreased when combined with Rucaparib.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Rucaparib.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Rucaparib.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Rucaparib.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Rucaparib.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Rucaparib.Approved, Investigational
NefazodoneThe metabolism of Rucaparib can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Rucaparib can be decreased when combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Rucaparib.Approved, Investigational
NetupitantThe serum concentration of Rucaparib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Rucaparib can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Rucaparib can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Rucaparib.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Rucaparib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Rucaparib.Approved
NilotinibThe metabolism of Rucaparib can be decreased when combined with Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Rucaparib.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Rucaparib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Rucaparib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Rucaparib.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Rucaparib.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Rucaparib.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Rucaparib.Approved, Investigational
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Rucaparib.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Rucaparib.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Rucaparib.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Rucaparib.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Rucaparib.Investigational
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Rucaparib.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Rucaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Rucaparib.Experimental, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Rucaparib.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Rucaparib.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Rucaparib.Approved
OpiumThe metabolism of Opium can be decreased when combined with Rucaparib.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Rucaparib.Approved
OsimertinibThe serum concentration of Rucaparib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Rucaparib.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Rucaparib.Approved
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Rucaparib.Approved, Investigational
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Rucaparib.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Rucaparib.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Rucaparib.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Rucaparib.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Rucaparib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Rucaparib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rucaparib.Approved, Vet Approved
PalbociclibThe serum concentration of Rucaparib can be increased when it is combined with Palbociclib.Approved, Investigational
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Rucaparib.Approved, Investigational
PanobinostatThe serum concentration of Rucaparib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Rucaparib.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Rucaparib.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Rucaparib.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Rucaparib.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Rucaparib.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Rucaparib.Approved, Investigational
ParoxetineThe metabolism of Rucaparib can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Rucaparib.Approved
Peginterferon alfa-2bThe serum concentration of Rucaparib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Rucaparib.Approved, Investigational
PentobarbitalThe metabolism of Rucaparib can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Rucaparib.Approved, Investigational
PerampanelThe metabolism of Perampanel can be decreased when combined with Rucaparib.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Rucaparib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Rucaparib.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Rucaparib.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Rucaparib.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Rucaparib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Rucaparib.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Rucaparib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Rucaparib.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
PhenobarbitalThe metabolism of Rucaparib can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Rucaparib.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Rucaparib.Approved, Investigational
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Rucaparib.Approved, Vet Approved
PhenytoinThe metabolism of Rucaparib can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Rucaparib.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Rucaparib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Rucaparib.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Rucaparib.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Rucaparib.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Rucaparib.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Rucaparib.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Rucaparib.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Rucaparib.Approved, Investigational
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Rucaparib.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Rucaparib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Rucaparib.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Rucaparib.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Rucaparib.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Rucaparib.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Rucaparib.Approved, Investigational
PosaconazoleThe metabolism of Rucaparib can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Rucaparib.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Rucaparib.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Rucaparib.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Rucaparib.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Rucaparib.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Rucaparib.Approved, Vet Approved
PrimaquineThe metabolism of Primaquine can be decreased when combined with Rucaparib.Approved
PrimidoneThe metabolism of Rucaparib can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Rucaparib.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Rucaparib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Rucaparib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Rucaparib.Approved
PromazineThe metabolism of Rucaparib can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Rucaparib.Approved, Investigational
PropafenoneThe serum concentration of Rucaparib can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Rucaparib.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Rucaparib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Rucaparib.Experimental
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Rucaparib.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Rucaparib.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Rucaparib.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Rucaparib.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Rucaparib.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Rucaparib.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Rucaparib.Approved, Investigational
QuinidineThe metabolism of Rucaparib can be decreased when combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Rucaparib can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Rucaparib.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Rucaparib.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Rucaparib.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Rucaparib.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Rucaparib.Approved, Investigational
RasagilineThe metabolism of Rasagiline can be decreased when combined with Rucaparib.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Rucaparib.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Rucaparib.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Rucaparib.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Rucaparib.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Rucaparib.Investigational
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Rucaparib.Approved, Experimental, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Rucaparib.Approved
RifabutinThe metabolism of Rucaparib can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Rucaparib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Rucaparib can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Rucaparib.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Rucaparib.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Rucaparib.Approved, Investigational
RimonabantThe metabolism of Rimonabant can be decreased when combined with Rucaparib.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Rucaparib.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Rucaparib.Approved, Investigational
RitonavirThe metabolism of Rucaparib can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Rucaparib.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Rucaparib.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Rucaparib can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Rucaparib.Approved, Investigational
RopiniroleThe metabolism of Rucaparib can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Rucaparib.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Rucaparib.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Rucaparib.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Rucaparib.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
RupatadineThe metabolism of Rupatadine can be decreased when combined with Rucaparib.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Rucaparib.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Rucaparib.Approved, Investigational
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Rucaparib.Approved
SaquinavirThe metabolism of Rucaparib can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Rucaparib can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Rucaparib.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Rucaparib.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Rucaparib.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
SertralineThe metabolism of Rucaparib can be decreased when combined with Sertraline.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Rucaparib.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Rucaparib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Rucaparib can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Rucaparib.Approved
SiltuximabThe serum concentration of Rucaparib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Rucaparib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Rucaparib.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Rucaparib.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Rucaparib.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Rucaparib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Rucaparib.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Rucaparib.Approved, Investigational
SparteineThe metabolism of Sparteine can be decreased when combined with Rucaparib.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Rucaparib.Approved
St. John's WortThe serum concentration of Rucaparib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Rucaparib can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Rucaparib.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Rucaparib.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Rucaparib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Rucaparib.Approved
SulfisoxazoleThe metabolism of Rucaparib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Rucaparib.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Rucaparib.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Rucaparib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Rucaparib.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Rucaparib.Approved
TacrineThe metabolism of Tacrine can be decreased when combined with Rucaparib.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Rucaparib.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Rucaparib.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Rucaparib resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Rucaparib.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Rucaparib.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Rucaparib.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Rucaparib.Experimental
TegaserodThe metabolism of Tegaserod can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Rucaparib can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Rucaparib can be decreased when combined with Telithromycin.Approved
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Rucaparib.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Rucaparib.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Rucaparib.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Rucaparib.Approved
Tenofovir disoproxilThe metabolism of Rucaparib can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Rucaparib.Approved
TerbinafineThe metabolism of Rucaparib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Rucaparib.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Rucaparib.Experimental
TeriflunomideThe serum concentration of Rucaparib can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Rucaparib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Rucaparib.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Rucaparib.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Rucaparib.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Rucaparib.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Rucaparib.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Rucaparib.Approved, Vet Approved
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Rucaparib.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Rucaparib.Approved, Investigational
TheophyllineThe metabolism of Rucaparib can be decreased when combined with Theophylline.Approved
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Rucaparib.Approved, Vet Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Rucaparib.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Rucaparib.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Rucaparib.Approved, Investigational
ThiothixeneThe metabolism of Thiothixene can be decreased when combined with Rucaparib.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Rucaparib.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Rucaparib.Approved
TiclopidineThe metabolism of Rucaparib can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Rucaparib.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Rucaparib.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Rucaparib.Approved
TipranavirThe metabolism of Rucaparib can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Rucaparib.Approved, Investigational
TocilizumabThe serum concentration of Rucaparib can be decreased when it is combined with Tocilizumab.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Rucaparib.Approved, Investigational
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Rucaparib.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Rucaparib.Approved, Investigational
TolperisoneThe metabolism of Tolperisone can be decreased when combined with Rucaparib.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Rucaparib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Rucaparib.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Rucaparib.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Rucaparib.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Rucaparib.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Rucaparib.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Rucaparib.Approved, Investigational
TranylcypromineThe metabolism of Rucaparib can be decreased when combined with Tranylcypromine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Rucaparib.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Rucaparib.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Rucaparib.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Rucaparib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Rucaparib.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Rucaparib.Approved, Vet Approved
TriamtereneThe metabolism of Triamterene can be decreased when combined with Rucaparib.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Rucaparib.Approved, Investigational
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Rucaparib.Approved, Investigational
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Rucaparib.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Rucaparib.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Rucaparib.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Rucaparib.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Rucaparib.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Rucaparib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Rucaparib.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Rucaparib.Approved
VadimezanThe metabolism of Vadimezan can be decreased when combined with Rucaparib.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Rucaparib.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Rucaparib.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Rucaparib.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Rucaparib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Rucaparib.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Rucaparib.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Rucaparib.Approved, Investigational
VemurafenibThe serum concentration of Rucaparib can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Rucaparib.Approved, Investigational
VenlafaxineThe metabolism of Rucaparib can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Rucaparib can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Rucaparib.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Rucaparib.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Rucaparib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Rucaparib.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Rucaparib.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Rucaparib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Rucaparib.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Rucaparib.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Rucaparib.Approved, Investigational
VoriconazoleThe metabolism of Rucaparib can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Rucaparib.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Rucaparib.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Rucaparib.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
YohimbineThe metabolism of Yohimbine can be decreased when combined with Rucaparib.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Rucaparib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Rucaparib.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Rucaparib.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Rucaparib.Approved, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Rucaparib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Rucaparib can be decreased when combined with Ziprasidone.Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Rucaparib.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Rucaparib.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Rucaparib.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Rucaparib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Rucaparib.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Rucaparib.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Rucaparib can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Rucaparib.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ: An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016 Aug 11;16:621. doi: 10.1186/s12885-016-2656-8. [PubMed:27515310]
  2. Jenner ZB, Sood AK, Coleman RL: Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun;12(12):1439-56. doi: 10.2217/fon-2016-0002. Epub 2016 Apr 18. [PubMed:27087632]
  3. Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer. 2016 Mar 29;114(7):723-30. doi: 10.1038/bjc.2016.41. Epub 2016 Mar 22. [PubMed:27002934]
  4. Dockery LE, Gunderson CC, Moore KN: Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther. 2017 Jun 19;10:3029-3037. doi: 10.2147/OTT.S114714. eCollection 2017. [PubMed:28790837]
  5. CENTER FOR DRUG EVALUATION AND RESEARCH [Link]
  6. Daily med. [Link]
  7. FDA Label [Link]
  8. wikipedia [Link]
  9. FDA List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) [Link]
External Links
KEGG Drug
D10079
PubChem Compound
9931954
PubChem Substance
347828593
ChemSpider
8107584
BindingDB
50446130
ChEBI
134689
ChEMBL
CHEMBL1173055
PharmGKB
PA166163418
HET
RPB
Wikipedia
Rucaparib
PDB Entries
4bjc / 4rv6
FDA label
Download (344 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingOtherNeoplasms1
1Active Not RecruitingOtherTumors, Solid1
1CompletedTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentNeoplasms, Gynecologic1
1RecruitingTreatmentSolid Tumor, Unspecified, Adult1
1, 2Active Not RecruitingTreatmentAdvanced Solid Tumor With Evidence of Germline or Somatic BRCA / Cancer of the Ovary / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
1, 2Not Yet RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Biliary System Disorder / BRCA1 Gene Mutation / Brca2 Gene Mutation / Homologous Recombination Deficiency / PALB2 Gene Mutation / Pancreatic Adenocarcinoma Metastatic / Stage IV Colorectal Cancer AJCC v7 / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v71
1, 2RecruitingTreatmentAdvanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer1
1, 2RecruitingTreatmentCancer, Advanced / Solid Tumors and Hematologic Malignancy1
2Active Not RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
2Active Not RecruitingTreatmentCancer, Breast1
2CompletedTreatmentBrca1 Mutation Carrier / Brca2 Mutation Carrier / Cancer of the Ovary / Cancer, Breast1
2CompletedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Ductal Adenocarcinoma1
2Not Yet RecruitingTreatmentATM Gene Mutation / BRCA1 Gene Mutation / Brca2 Gene Mutation / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Homologous Recombination Deficiency / Prostate Carcinoma Metastatic in the Bone / PSA Level Greater Than or Equal to Two / PSA Progression / Stage IV Prostate Adenocarcinoma AJCC v71
2Not Yet RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
2RecruitingTreatmentAdenocarcinoma of the Gastro-oesophageal Junction / Adenocarcinoma of the Oesophagus / Adenocarcinoma of the Stomach1
2RecruitingTreatmentBladder Cancers / Muscle Invasive Bladder Cancer / Renal Pelvis Carcinoma / Transitional Cell Carcinoma / Ureter Carcinoma / Urethra Carcinoma / Urinary Bladder Carcinoma / Urothelial carcinoma ureter metastatic1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
2RecruitingTreatmentProstate Cancer1
2WithdrawnTreatmentDiabetes Mellitus (DM) / Retinopathy, Diabetic1
3Active Not RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
3RecruitingTreatmentCancer of the Ovary / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Epithelial Cancer1
3RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral300 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8859562No2011-08-042031-08-04Us
US8143241No2007-08-122027-08-12Us
US6495541No2000-01-102020-01-10Us
US8754072No2011-02-102031-02-10Us
US9045487No2011-02-102031-02-10Us
US8071579No2007-08-122027-08-12Us
US7531530No2004-07-232024-07-23Us
US7351701No2004-07-232024-07-23Us
US9861638No2011-02-102031-02-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility1 mg/mLFDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.0114 mg/mLALOGPS
logP2.39ALOGPS
logP2.45ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)13.16ChemAxon
pKa (Strongest Basic)9.32ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area56.92 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity92.91 m3·mol-1ChemAxon
Polarizability35.19 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 2-phenylindoles. These are indoles substituted at the 2-position with a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
2-phenylindoles
Alternative Parents
Phenylpyrroles / Benzazepines / 3-alkylindoles / Phenylmethylamines / Benzylamines / Aralkylamines / Azepines / Aryl fluorides / Heteroaromatic compounds / Secondary carboxylic acid amides
show 9 more
Substituents
2-phenylindole / Benzazepine / 2-phenylpyrrole / 3-alkylindole / Benzylamine / Phenylmethylamine / Aralkylamine / Azepine / Benzenoid / Aryl fluoride
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This ...
Gene Name
PARP1
Uniprot ID
P09874
Uniprot Name
Poly [ADP-ribose] polymerase 1
Molecular Weight
113082.945 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Nad+ adp-ribosyltransferase activity
Specific Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This ...
Gene Name
PARP2
Uniprot ID
Q9UGN5
Uniprot Name
Poly [ADP-ribose] polymerase 2
Molecular Weight
66205.31 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Nad+ adp-ribosyltransferase activity
Specific Function
Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This ...
Gene Name
PARP3
Uniprot ID
Q9Y6F1
Uniprot Name
Poly [ADP-ribose] polymerase 3
Molecular Weight
60069.7 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
Inhibitor
Inducer
Other (add new)
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
Inhibitor
Downregulator
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monovalent cation:proton antiporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfat...
Gene Name
SLC47A1
Uniprot ID
Q96FL8
Uniprot Name
Multidrug and toxin extrusion protein 1
Molecular Weight
61921.585 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Drug transmembrane transporter activity
Specific Function
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acy...
Gene Name
SLC47A2
Uniprot ID
Q86VL8
Uniprot Name
Multidrug and toxin extrusion protein 2
Molecular Weight
65083.915 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da

Drug created on October 20, 2016 15:59 / Updated on March 02, 2018 05:27